PMID- 28429115
OWN - NLM
STAT- MEDLINE
DCOM- 20180301
LR  - 20181113
IS  - 1432-1076 (Electronic)
IS  - 0340-6199 (Linking)
VI  - 176
IP  - 6
DP  - 2017 Jun
TI  - Comparison of the tolerability of newly introduced childhood vaccines in the 
      Netherlands.
PG  - 757-768
LID - 10.1007/s00431-017-2901-4 [doi]
AB  - In 2011, the 7-valent conjugated pneumococcal vaccine (PCV7) was replaced by the 
      10-valent vaccine (PCV10) and universal hepatitis B vaccination has been 
      introduced in the Netherlands. A questionnaire study was conducted to assess the 
      tolerability of DTaP-IPV-Hib + PCV7 (PCV7-cohort), DTaP-IPV-Hib + PCV10 
      (PCV10-cohort), and DTaP-IPV-Hib-HepB + PCV10 (HepB-cohort). Parents were asked 
      to report in questionnaires local reactions and systemic adverse events (AEs) 
      before and after vaccination of their infant at 2, 3, 4, and 11 months of age. 
      For 29.0 and 29.4% infants of the PCV7-cohort, at least one local reaction was 
      reported in the week after the first dose of DTaP-IPV (left leg) and PCV-7 
      vaccination (right leg). Significantly more infants from the PCV10-cohort (45.1%, 
      p < 0.001 and 44.6%, p < 0.001) and HepB-cohort (42.6%, p < 0.001 and 41.9%, 
      p < 0.001) reported at least one local reaction. This effect was less pronounced 
      after the successive doses. Most of the infants experienced at least one systemic 
      AE, and after dose 4, this was higher for infants in the PCV10-cohort (65.9%, 
      p = 0.047) and HepB-cohort (70.6%, p = 0.000) compared to the PCV7-cohort 
      (62.3%). CONCLUSION: Addition of antigens to a vaccine resulted in a higher 
      reactogenicity, but the AEs were in general mild and transient. What is Known: * 
      Assessment of adverse events is crucial for achieving the highest safety in 
      immunization programs, in order to inform public health actions and maintain 
      public confidence in immunization programs. What is New: * Newly introduced 
      vaccines DTaP-IPV-Hib-HepB and PCV10 are generally safe and well tolerated in 
      infants. * These results are useful for information purposes and for monitoring 
      variations in rates of AEs in the general population or in the target group over 
      time.
FAU - Kemmeren, Jeanet M
AU  - Kemmeren JM
AD  - Center for Infectious Disease Control, National Institute for Public Health and 
      the Environment, P.O. Box 1, 3720 BA, Bilthoven, The Netherlands. 
      jeanet.kemmeren@rivm.nl.
FAU - van der Maas, Nicoline At
AU  - van der Maas NA
AD  - Center for Infectious Disease Control, National Institute for Public Health and 
      the Environment, P.O. Box 1, 3720 BA, Bilthoven, The Netherlands.
FAU - de Melker, Hester E
AU  - de Melker HE
AD  - Center for Infectious Disease Control, National Institute for Public Health and 
      the Environment, P.O. Box 1, 3720 BA, Bilthoven, The Netherlands.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20170420
PL  - Germany
TA  - Eur J Pediatr
JT  - European journal of pediatrics
JID - 7603873
RN  - 0 (10-valent pneumococcal conjugate vaccine)
RN  - 0 (Diphtheria-Tetanus-Pertussis Vaccine)
RN  - 0 (Haemophilus Vaccines)
RN  - 0 (Hepatitis B Vaccines)
RN  - 0 (Pneumococcal Vaccines)
RN  - 0 (Poliovirus Vaccine, Inactivated)
RN  - 0 (Vaccines, Conjugate)
RN  - 0 (diphtheria-tetanus-five component acellular pertussis-inactivated 
      poliomyelitis -Haemophilus influenzae type b conjugate vaccine)
SB  - IM
MH  - Diphtheria-Tetanus-Pertussis Vaccine/*adverse effects
MH  - Female
MH  - Haemophilus Vaccines/*adverse effects
MH  - Health Care Surveys
MH  - Hepatitis B Vaccines/*adverse effects
MH  - Humans
MH  - Immunization Schedule
MH  - Infant
MH  - Male
MH  - Models, Statistical
MH  - Netherlands
MH  - Pneumococcal Vaccines/*adverse effects
MH  - Poliovirus Vaccine, Inactivated/*adverse effects
MH  - Vaccines, Conjugate/adverse effects
OTO - NOTNLM
OT  - Hexavalent vaccine
OT  - Infants
OT  - Pentavalent vaccine
OT  - Pneumococcal vaccine
OT  - Reactogenicity
OT  - Tolerability
EDAT- 2017/04/22 06:00
MHDA- 2018/03/02 06:00
CRDT- 2017/04/22 06:00
PHST- 2016/10/25 00:00 [received]
PHST- 2017/03/24 00:00 [accepted]
PHST- 2017/03/22 00:00 [revised]
PHST- 2017/04/22 06:00 [pubmed]
PHST- 2018/03/02 06:00 [medline]
PHST- 2017/04/22 06:00 [entrez]
AID - 10.1007/s00431-017-2901-4 [pii]
AID - 10.1007/s00431-017-2901-4 [doi]
PST - ppublish
SO  - Eur J Pediatr. 2017 Jun;176(6):757-768. doi: 10.1007/s00431-017-2901-4. Epub 2017 
      Apr 20.